Is the price fair?
What ADMA's price assumes
ADMA Biologics, Inc. trades at 14.0× earnings against 31.5× for the median Biotechnology name, cheaper than its own group.
14.0
Trailing P/E · Biotechnology median 31.5 · cheaper than the typical name in its group
- Price / sales
- 4.24
Price / sales · as of 2026-Q1
- Free cash flow yield
- 5.3%
Free cash flow yield · Biotechnology median 2.4%
- Growth the price implies
- +4.8%
Growth the price implies · The price pays for +4.8% free cash flow growth a year for a decade; revenue has grown +41% a year over the last three.
Details›
- Price / book2026-Q1
- 5.54
- EV / EBIT2026-Q1
- 10.3
- EV / sales2026-Q1
- 4.36
- Healthcare median P/E362 names
- 29.9
- Biotechnology median P/E158 names
- 31.5
- Free cash flow, trailing twelve months
- $108M
- Market capitalisation
- $2.02B
- 3-year revenue growth
- +41%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.